Merit Medical Systems (MMSI) Acquires Peritoneal Dialysis Maker Medigroup
Tweet
Share
E-mailGet Alerts MMSI Hot Sheet
Join SI Premium – FREE
Merit Medical Systems, Inc. (Nasdaq: MMSI) announced that it has acquired substantially all of the assets of Medigroup, Inc., a manufacturer of peritoneal dialysis catheters based in Illinois.
"Medigroup offers a broad product line of catheters and implantation devices, and we believe this opportunity will enhance our overall dialysis business," said Fred P. Lampropoulos, Chairman and Chief Executive Officer of Merit Medical. "Medigroup's current annual sales are approximately $2 million, mostly in the United States, and we plan to offer the product line immediately on a worldwide basis. While growing in the United States, peritoneal dialysis is the procedure of choice over chronic catheters in many international markets. Medigroup is profitable, with 75% gross margins, and we believe the transaction will be immediately accretive for us."
"Medigroup offers a broad product line of catheters and implantation devices, and we believe this opportunity will enhance our overall dialysis business," said Fred P. Lampropoulos, Chairman and Chief Executive Officer of Merit Medical. "Medigroup's current annual sales are approximately $2 million, mostly in the United States, and we plan to offer the product line immediately on a worldwide basis. While growing in the United States, peritoneal dialysis is the procedure of choice over chronic catheters in many international markets. Medigroup is profitable, with 75% gross margins, and we believe the transaction will be immediately accretive for us."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merit Medical names new EVP of global operations as COO prepares to exit
- Dover to acquire India-based cryogenic valve maker Leistung
- EigenQ files draft S-4 with SEC in SPAC merger with Silicon Valley Acquisition
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
